In Part D, designed to support Phase III, dosing was determined by LVOT-G for oHCM and NT-proBNP for nHCM.
— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to ...
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues ...
The poster outlines the scientific background, study design, and clinical rationale for the Company’s ongoing Phase 2 trial evaluating stenoparib in patients with advanced plati ...
Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide ...
Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction–associated steatohepatitis ...
After rapidly growing prevalence over the past four decades, overweight and obesity now affect more than half of adult population in China 1. Often clustered with hypertension, dyslipidemia, ...
Discussing the next entry, Brener notes, "It's testing through the roof, and we're only at the director's cut, the 10-week part of the movie where you're normally very, very scared about the status of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results